Shire Finally Able To Move Firazyr Forward
This article was originally published in The Pink Sheet Daily
Executive Summary
Shire reports positive phase III results for its HAE drug and may file a complete response in the next few months.
You may also be interested in...
Despite Rival's Supply Problems, No Guarantee That Shire Will Re-File Replagal In U.S.
Human Genetic Therapies division President Gregoire also says self-administration should be a key point of differentiation for Firazyr in the HAE market.
Despite Rival's Supply Problems, No Guarantee That Shire Will Re-File Replagal In U.S.
Human Genetic Therapies division President Gregoire also says self-administration should be a key point of differentiation for Firazyr in the HAE market.
Shire Says Vpriv Is A Viable Option for Cerezyme Patients; Gets PDUFA For Firazyr
Firazyr could enjoy a dosing advantage over other HAE drugs currently on the U.S. marketplace if it can get approval from FDA.